Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation
Autore:
Skull, SA; Butler, JRG; Robinson, P; Carnie, J;
Indirizzi:
Royal Melbourne Hosp, Victoria Infect Dis Serv, Parkville, Vic 3050, Australia Royal Melbourne Hosp Parkville Vic Australia 3050 le, Vic 3050, Australia
Titolo Testata:
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
fascicolo: 3, volume: 30, anno: 2001,
pagine: 571 - 578
SICI:
0300-5771(200106)30:3<571:SPFCMV>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONJUGATE VACCINE; POLYSACCHARIDE; INDUCTION; ADULTS; TRIAL;
Keywords:
Neisseria meningitidis; cost-effectiveness analysis; immunization programmes; health planning;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Skull, SA Royal Melbourne Hosp, Victoria Infect Dis Serv, Parkville, Vic 3050, Australia Royal Melbourne Hosp Parkville Vic Australia 3050 50, Australia
Citazione:
S.A. Skull et al., "Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation", INT J EPID, 30(3), 2001, pp. 571-578

Abstract

Background Disease due to serogroup C Neisseria meningitidis is life-threatening and potentially preventable by vaccination. In 1999, the UK instigated mass vaccination after a sustained increase in serogronp C meningococcaldisease. Ln the same year, Victoria, Australia experienced a similar change in disease epidemiology. It is timely to undertake an economic evaluationof options for community vaccination in Australia based on local data. Methods Cost-effectiveness and cost-benefit analyses of three options for use of polysaccharide vaccine were undertaken for a hypothetical populationaged 15-19 years. Baseline analyses assumed 5 years' duration of vaccine protection following a single year of programme implementation. Sensitivity analyses of key variables were performed, including vaccine coverage and effectiveness, case fatality rate and the discount rate. Outcomes included the number of people vaccinated, cases averted, life-years saved and disability-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earnings avoided as a measure of vaccination benefit. Results Vaccination of people aged 15-19 years in a defined population with a high rate of disease was the most cost-effective option. Compared with no vaccination and assuming 5 years' duration of protection and exclusion of direct cost savings, this resulted in a discounted cost per life-year saved of $23 623, a cost per DALY avoided of $21 097 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option with exclusion of direct cost savings was 14.0/100 000. Conclusions Community use of polysaccharide vaccination may be cost effective in Australia under certain conditions. Economic evidence favours use ofvaccination in well-defined populations with a high rate of disease. Policy decision-making also requires consideration of non-economic factors, including feasibility of implementation and risk perception by the community.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/01/21 alle ore 23:08:57